| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2006 | US20060166953 Ciclesonide-containing sterile aqueous suspension |
| 07/27/2006 | US20060166952 Cardenolide glycosides, which have a cytotoxic activity, cancer |
| 07/27/2006 | US20060166951 Compositions and methods for sterol isolation and purification |
| 07/27/2006 | US20060166950 Treatment of neovascularization disorders with squalamine |
| 07/27/2006 | US20060166949 Vitamin d analogues, compositions comprising said analogues and their use |
| 07/27/2006 | US20060166948 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries |
| 07/27/2006 | US20060166947 Multiple myeloma treatments |
| 07/27/2006 | US20060166946 Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 07/27/2006 | US20060166945 Substituted tetracycline compounds |
| 07/27/2006 | US20060166944 tetracycline derivatives such as 4-Oximinominocycline, used for the treatment of bacterial infections, as antitumor agents, blocking tetracycline efflux and modulation of gene expression |
| 07/27/2006 | US20060166943 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission |
| 07/27/2006 | US20060166942 combretastatin A4 phosphate mono-tromethamine in crystalline solid state; salt form increases solubility of combretastatin A4; regenerates native combretastatin A-4 in vivo and do not produce unwanted or potentially deleterious side products when undergoing regeneration |
| 07/27/2006 | US20060166941 Treatment and/or prevention of non-viral epithelial damage |
| 07/27/2006 | US20060166940 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases |
| 07/27/2006 | US20060166938 Method of treatment using bisphosphonic acid |
| 07/27/2006 | US20060166937 Bisphosphonates for the treatment of atherosclerosis and device comprising them |
| 07/27/2006 | US20060166936 Diaminotriazole compounds useful as inhibitors of protein kinases |
| 07/27/2006 | US20060166935 Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| 07/27/2006 | US20060166934 Composition comprising phytosphingosine derivatives for apoptosis induction |
| 07/27/2006 | US20060166933 Novel 2H-chromene derivatives as selective estrogen receptor modulators |
| 07/27/2006 | US20060166932 Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
| 07/27/2006 | US20060166931 Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof |
| 07/27/2006 | US20060166930 Pharmaceutical composition for dry eye, which remains on the cornea and exhibits a humectant effect for a longer period |
| 07/27/2006 | US20060166929 Sugar-chain asparagine derivatives and processes for the preparation thereof |
| 07/27/2006 | US20060166928 Hyaluronic acid derivative gel and method for preparing the same |
| 07/27/2006 | US20060166927 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 07/27/2006 | US20060166926 small molecules that modulate premature translation termination and/or nonsense-mediated mRNA decay; treating cystic fibrosis or muscular dystrophy |
| 07/27/2006 | US20060166925 Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 07/27/2006 | US20060166923 Immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides |
| 07/27/2006 | US20060166907 Composition for the treatment of nasopharyngeal carcinoma and method of use thereof |
| 07/27/2006 | US20060166906 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance |
| 07/27/2006 | US20060166905 Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale |
| 07/27/2006 | US20060166904 Prepared by hydrolysis of azithromycin derivatives to remove 4-O-methylcladinose from position 3 |
| 07/27/2006 | US20060166903 Phosphocholine linked prodrug derivatives |
| 07/27/2006 | US20060166902 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
| 07/27/2006 | US20060166901 Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| 07/27/2006 | US20060166900 Salt of morphine-6-glucuronide |
| 07/27/2006 | US20060166899 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole |
| 07/27/2006 | US20060166895 N-heterocyclic hydroxyethylamine compounds; human immunodeficiency virus (HIV) protease |
| 07/27/2006 | US20060166894 Ace-inhibitors having antioxidant and no-donor activity |
| 07/27/2006 | US20060166893 Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments |
| 07/27/2006 | US20060166892 Treatment of cell proliferative disorders with chlorotoxin |
| 07/27/2006 | US20060166889 Chimeric peptides that facilitate the transport of insulin across biological membranes that have a first domain having a specific translocation sequence and a second domain having at least a biologically active portion of an insulin polypeptide; treatment of diabetes |
| 07/27/2006 | US20060166886 Polyethylene glycol-albumin colloid that reduces the risk of organ injury and treats hypovolemic conditions by restoring vascular volumes; treating multiorgan dysfunction (MODS), related to systemic inflammatory response syndrome (SIRS); pegylated albumin has an extended useful half-life |
| 07/27/2006 | US20060166879 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| 07/27/2006 | US20060166872 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia |
| 07/27/2006 | US20060166870 Treatment of glioblastoma with thymosin-alpha 1 |
| 07/27/2006 | US20060166867 Argininamido-neomycin B conjugates; aminoglycoside antibiotics; for prevention and treatment of HIV infection |
| 07/27/2006 | US20060166866 Cell adhesion inhibitors |
| 07/27/2006 | US20060166865 A modified nucleoside comprising a purine ring for treating viral infections |
| 07/27/2006 | US20060166863 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 07/27/2006 | US20060166862 Comprising a transcobalamin (TC) binding carrier and a therapeutic and/or diagnostic agent linked directly or through linker to the TC binding carrier; highly and efficiently absorbed |
| 07/27/2006 | US20060166859 Compounds and compositions for delivering active agents |
| 07/27/2006 | US20060166841 Process for the preparation of phenothiazine granules having improved properties |
| 07/27/2006 | US20060166824 Avermectin and avemectin monosaccharide derivatives substituted in the 4"-or 4'-position having pesticidal properties |
| 07/27/2006 | US20060166341 Method for reproducing pleuromutilins |
| 07/27/2006 | US20060166325 Glial cell line-derived neurotrophic factor receptor |
| 07/27/2006 | US20060166295 Method for determination of likelihood of occurrence of preterm labor in pregnant females |
| 07/27/2006 | US20060166281 Tissue targeted therapy; identifying antitumor agents specific to transphosphorylase domain of c-kit; interleulin-3 cell targeting |
| 07/27/2006 | US20060166275 Amyloid beta protein (globular assembly and uses thereof) |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060166208 Induction of the mitochondrial permeability transition |
| 07/27/2006 | US20060166194 Diagnosis and treatment of cancer |
| 07/27/2006 | US20060166193 Binding protein |
| 07/27/2006 | US20060165827 Anti diarrhoea compositions |
| 07/27/2006 | US20060165821 Composition comprising scutellaria baicalensis and their uses thereof |
| 07/27/2006 | US20060165820 Herbal supplement to support weight loss |
| 07/27/2006 | US20060165819 Topical composition for the treatment of psoriasis and related skin disorders |
| 07/27/2006 | US20060165816 Herbal compositions useful as chemopreventive and therapeutic agents |
| 07/27/2006 | US20060165815 Choline-silicic acid complex with osmolytes and divalent trace elements |
| 07/27/2006 | US20060165814 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
| 07/27/2006 | US20060165810 Controlled release from block co-polymer worm micelles |
| 07/27/2006 | US20060165808 Microcapsules for the delayed, controlled release of perindopril |
| 07/27/2006 | US20060165807 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| 07/27/2006 | US20060165804 Polymer compositions for administration to animals |
| 07/27/2006 | US20060165803 Pharmaceutical compositions of sertaconazole for vaginal use |
| 07/27/2006 | US20060165801 Hydrous gel and production process and use of the hydrous gel |
| 07/27/2006 | US20060165797 Dosage form for treating gastrointestinal disorders |
| 07/27/2006 | US20060165796 Extended release formulation of levetiracetam |
| 07/27/2006 | US20060165795 Medicinal compositions comprising a core and a film based on modified cellulose derivatives |
| 07/27/2006 | US20060165793 Pharmaceutical preparation to be dispersed before administration |
| 07/27/2006 | US20060165792 Controlled release oxycodone compositions |
| 07/27/2006 | US20060165791 Oral dosage form prepared by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules; improving efficiency and quality of pain management |
| 07/27/2006 | US20060165790 Multiparticulates |
| 07/27/2006 | US20060165789 Lercanidipine modified release compositions |
| 07/27/2006 | US20060165788 Lercanidipine pH dependent pulsatile release compositions |
| 07/27/2006 | US20060165786 Methods for treating circadian rhythm phase disturbances |
| 07/27/2006 | US20060165785 Method of chemically stabilizing pharmaceutical formulations with cholesterol |
| 07/27/2006 | US20060165783 Compacted lactic acid menthyl ester |
| 07/27/2006 | US20060165782 Solid compositions comprising gabapentin having improved stability |
| 07/27/2006 | US20060165780 Anticoagulant composition |
| 07/27/2006 | US20060165779 Novel method stabilizing bupropion hydrochloride tablets |
| 07/27/2006 | US20060165778 Enteric composition for the manufacture of soft capsule wall |
| 07/27/2006 | US20060165776 Antidepressant oral pharmaceutical compositions |
| 07/27/2006 | US20060165772 Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts |
| 07/27/2006 | US20060165771 Compositions for delivery of drug combinations |
| 07/27/2006 | US20060165769 Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations |
| 07/27/2006 | US20060165763 Pasting agent |
| 07/27/2006 | US20060165761 Wound dressings comprising vanadate complexed with organic ligands |
| 07/27/2006 | US20060165758 Blunting the postprandial glycemic response by instant feed containing proteins, fats, carbohydrates, neutral soluble dietary fiber (guar gum, pectin, locust bean gum, methylcellulose), and hydrolyzed starch; diabetes |